Patients in the intensive care unit (ICU) frequently receive proton pump inhibitors (PPIs) and have high rates of Clostridium diffi cile infection (CDI). PPIs have been associated with CDI in hospitalized patients, but ICU patients differ fundamentally from non-ICU patients and few studies have focused on PPI use exclusively in the critical care setting. We performed a retrospective cohort study to determine the associations between PPIs and health-care facility-onset CDI in the ICU.
INTRODUCTION
Clostridium diffi cile infection (CDI) is a rising cause of healthcare-associated infections and is associated with worse outcomes ( 1,2 ) and increased costs among hospitalized patients ( 3, 4 ) . In the United States, there are an estimated 450,000 cases of CDI annually ( 5 ), and C. diffi cile causes 12% of all health-care-associated infections ( 6 ) . Patients hospitalized in intensive care units (ICUs) are at increased risk for CDI compared with other in-patients ( 7 ), and mortality rates for ICU patients with CDI exceed baseline ICU mortality rates ( 8 ) .
Risk factors associated with the development of CDI have been studied extensively in the community (9) (10) (11) (12) (13) (14) and among in-patients (15) (16) (17) (18) (19) (20) (21) , but the risk factors for the onset of CDI among ICU patients have received less attention (22) (23) (24) (25) (26) . Among hospitalized patients, established risk factors for incident CDI include older age and comorbid medical conditions such as impaired renal function and low serum albumin ( 27, 28 ) . Potentially modifi able risk factors associated with hospital-onset CDI include receipt of antibiotics and receipt of proton pump inhibitors (PPIs) ( 29, 30 ) .
Critically ill patients diff er from patients hospitalized on a general medical or surgical fl oor. CDI is the archetypal disease of the gastrointestinal microbiome, and loss of normal fecal microbial diversity oft en precedes CDI ( 31 ) . Compared with other inpatients, ICU patients have very low fecal microbial diversity, which further declines during treatment in the ICU ( 32 ) . Additionally, ICU patients are more likely to receive PPIs for stress ulcer prophylaxis or active gastrointestinal bleeding. In the ICU compared with other hospital locations, there is increased use of antibiotics, luminal penetration of antibiotics, gut wall edema, and derangements in gastrointestinal motility ( 33 ) . For all of these reasons, traditional risk factors such as antibiotics and PPIs may have distinct relationships with risk for CDI when CDI arises in the ICU setting. We performed a retrospective cohort study to determine the crucial risk factors for health-care facility-onset CDI in the ICU, focusing on PPIs. A priori , we hypothesized that PPIs are associated with increased risk for CDI in the ICU and that, when PPIs are given concomitantly with antibiotics, there is an additive or multiplicative increase in risk for CDI.
METHODS

Study population
We conducted a retrospective cohort study of all adult patients (≥18 years old at the time of admission) admitted to any one of 14 distinct ICUs at three affi liated university hospitals between 1 January 2010 and 30 December 2013. We chose 2010 for the study's start date because it was the fi rst full calendar year during which these institutions all used the stool PCR test for the C. diffi cile toxin B gene for the diagnosis of CDI. Patients were excluded from the study if they had an ICU stay of <3 days. Because the risk factors for recurrent CDI may diff er from the risk factors for incident CDI, we also excluded patients if they had a positive stool test for C. diffi cile during the 90 days preceding ICU admission ( 19 ) . If patients had multiple ICU admissions, only their fi rst ICU admission was included in the analysis. Electronically available data obtained through the project Health Information Technology to Reduce Health-Care-Associated Infections were used for cross-validation of our sample cohort. Th e study was approved by the institutional review boards at the Columbia University Medical Center, the Allen Hospital, and Weill Cornell Medical College.
Health-care facility-onset CDI in the ICU
CDI was defi ned as a newly positive stool test for C. diffi cile toxin B from an unformed stool followed by initiation of appropriate therapy (i.e., metronidazole or oral vancomycin) for CDI. For this study, the day of CDI onset was the day on which the positive stool sample was produced. Health-care facility-onset CDI in the ICU was conservatively defi ned as CDI that occurred >3 days aft er admission to the ICU, consistent with current guidelines describing health-care facility-onset infections as those occurring 48 to 72 h aft er admission ( 34 ) .
Risk factors
We parsed electronic medical records and extracted risk factor information using automated queries. We examined the following potential risk factors for health-care facility-onset CDI in the ICU: demographics; creatinine (continuous, mg/dl), white blood cell count (continuous, cells per μ l and categorical, normal 3.5-9.1 K vs. abnormal <3.5 or >9.1 K) and albumin (continuous, g/dl) at the time of ICU admission; ICU type (medical, surgical, cardiac, neurological); ICU length of stay (days); and ICU therapies as categorical variables including mechanical ventilation, hemodialysis (including both continuous venovenous hemodialysis and intermittent hemodialysis), immunosuppressants (including systemic steroids at a minimum daily dose of 5 mg prednisone or equivalent, calcineurin inhibitors, anti-metabolites, anti-TNFα agents, or mycophenolic acid), antibiotics (classifi ed as exposed/ unexposed, number of individual antibiotics exposed, and additionally organized according to antibiotic class), H2 receptor antagonists (H2RAs, classifi ed as exposed/unexposed), and PPIs. In the primary analysis, subjects were classifi ed as exposed or not unexposed to PPIs based on receipt of an oral or intravenous PPI at any dose or duration. In an additional sensitivity analysis, we assessed for a dose-response eff ect between PPIs and health-care facility-onset CDI in the ICU by classifying PPI exposure according to the average daily dose of PPIs received.
All medication exposures were classifi ed based on when they were actually administered as opposed to when they were ordered; this information was retrieved from the computerized provider order entry system. Variables gathered at the time of ICU admission, such as demographic information and comorbid conditions, were treated as time-fi xed. Exposures that occurred during the ICU stay, including receipt of antibiotics and PPIs, were analyzed as time-varying covariates (classifi ed as absent until the time of initial exposure following ICU admission and thereaft er as present). Th is refl ects the observation that risk for CDI remains steadily elevated for over 30 days following receipt of antibiotics or similar exposures ( 35 ) ).
Our electronic medical record uses standard International Classifi cation of Diseases (ICD) coding to describe patient comorbidities. Our previous work has shown that ICD coding of patient comorbidities is oft en inaccurate compared with manual review ( 19 ) , a problem that others have also described ( 36 ) . To better capture patient comorbidities, we additionally used a natural language processing system that transforms clinical text pertaining to medical comorbidities into computable data, with methods we have described previously ( 37 ) . Th is information was extracted in an automated manner as the components of the Charlson comorbidity index ( 38 ) .
Statistical analysis
For continuous variables, we computed means (if data were normally distributed) or medians and interquartile ranges, and compared these variables using Student's t -test or the MannWhitney U -test. We compared categorical variables using the χ 2 test. Our multivariable analysis was constructed using a Cox proportional hazards model with patients followed for 30 days or until death, ICU discharge, or the onset of CDI. To build the fi nal model, we fi rst tested for interactions between individual predictor variables and PPIs; when there was evidence of a signifi cant interaction ( P <0.05), we included the relevant variable along with an appropriate interaction term. Variables were then added stepwise to the fi nal model and included if they had a signifi cant relationship with health-care facility-onset CDI in the ICU ( P <0.05) or if they changed the β -coeffi cient representing PPIs by ≥10%. To assess for the possibility of death as a competing risk for CDI, we conducted a restriction analysis among the subset of patients who survived to ICU discharge or CDI. To determine whether inclusion of patients at risk for recurrent CDI would alter our fi ndings, we conducted a sensitivity analysis including patients who were diagnosed with CDI within 90 days before ICU admission. Statistical analyses were performed using the statistical soft ware Stata version 12. A P -value of <0.05 was considered statistically signifi cant.
RESULTS
Health-care facility-onset CDI in the ICU
Of 39,535 unique adult patients admitted to intensive care during the study period, 18,134 met the eligibility criteria and 271 of these (1.5%) developed health-care facility-onset CDI in the ICU ( Figure 1 ) . Th e median interval between ICU admission and diagnosis of CDI was 7 days (interquartile range 5-11). Compared with ICU patients without CDI, those who developed CDI had increased mortality during the index ICU stay (23% vs. 9%, respectively, P <0.01) and the index hospital stay (30% vs. 14%, respectively, P< 0.01).
Baseline risk factors
At the time of admission to intensive care, those who later developed health-care facility-onset CDI in the ICU had higher serum creatinine and lower serum albumin values than those who never developed CDI ( P <0.01 for both; Table 1 ). CDI occurred more oft en in the neurological ICU than in other ICU types ( P <0.01). Th e Charlson comorbidity index score was signifi cantly higher in those who developed CDI compared with those who did not ( P <0.01), with cerebrovascular disease, chronic kidney disease, chronic obstructive pulmonary disease, and diabetes, each associated with increased risk for CDI.
Risk factors during ICU treatment
Mechanical ventilation, hemodialysis, and receipt of antibiotics were associated with health-care facility-onset CDI in the ICU ( Table 2 ) . Th e antibiotic classes individually associated with signifi cantly increased risk for CDI were β -lactam/β -lactamase inhibitors (including piperacillin-tazobactam, amoxicillin-clavulanate, and ampicillin-sulbactam, with combined adjusted HR (aHR) 1.71; 95% confi dence interval (95% CI), 1.30-2.27) as well as intravenous vancomycin (aHR 1.42; 95% CI, 1.05-1.92). Fluoroquinolones were not signifi cantly associated with CDI (aHR 1.03; 95% CI, 0.67-1.59) nor were cephalosporins (aHR 0.77; 95% CI, 0.56-1.07) ( Supplementary Table 1 ). Rates of health-care facility-onset CDI in the ICU increased as the number of concurrent antibiotics increased (0.5% in those who received no antibiotics, 1% in those who received only one antibiotic, and 2.6% in those who received two or more diff erent antibiotics), but this trend was not signifi cant when tested in our fi nal model ( P =0.71).
Th e cumulative incidence of CDI was 0.4% in those who received no antibiotics or PPIs, 0.7% in those who received PPIs but no antibiotics, 2.7% in those who received antibiotics and no PPIs, and 1.6% in those who received both antibiotics and PPIs ( P <0.01; Figure 2 ). Th ere was no evidence of a dose-based relationship between PPIs and CDI ( Supplementary Table 2 ). Again, there was the suggestion that the relationship between PPIs and CDI depended, in part, on concurrent antibiotic exposure. Neither PPIs nor antibiotics were risk factors for worse outcomes aft er CDI as measured by 90-day mortality rates, which were 36% for those exposed to PPIs vs. 33% for those not exposed ( P =0.56) and 35% for those exposed to antibiotics vs. 31% for those not exposed 
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and PPIs while in the ICU ( Table 3 ). Th ese relationships were similar when we analyzed only the subjects who survived to ICU discharge and also similar when we included in the analysis an additional 146 subjects who had been diagnosed with CDI within the 90 days before ICU admission. Th ere was evidence of a significant interaction between antibiotics and PPIs (interaction term P =0.01) and PPIs were included in the multivariable model using an interaction term for antibiotics. Th ere were no other signifi cant interactions with PPIs. Aft er stratifying by receipt of antibiotics, PPIs were not associated with increased risk for CDI in those who who did not receive antibiotics (aHR 1.56; 95% CI, 0.72-3.35), and PPIs were actually associated with a decreased risk for CDI in those who received antibiotics (aHR 0.64; 95% CI, 0.48-0.83).
DISCUSSION
In a large, multicenter retrospective cohort of adult patients hospitalized in intensive care for 3 days or more, we found that serum creatinine at the time of ICU admission, admission to a neurological ICU, and receipt of antibiotics were associated with health-care facility-onset CDI in the ICU. Receipt of PPIs was not signifi cantly associated with CDI in the intensive care setting, and this remained true when we examined patients who received PPIs at higher total doses. Th ere was evidence that antibiotics modifi ed the PPI-CDI relationship. Antibiotics predispose to colonization and infection by C. diffi cile through alterations in the intestinal fl ora ( 39 ) . In our study, certain broad-spectrum antibiotics with anaerobic and Gram-negative coverage were associated with increased risk for CDI. Cephalosporins and fl uoroquinolones, which have ( P =0.66). Exposure to H2RAs without PPIs was rare in our cohort (6.4%) and there was no diff erence in rates of CDI between those who were and were not exposed to H2RAs (1.3% vs. 1.8%, respectively, P =0.27).
Multivariable model
Our fi nal multivariable model included ICU type, serum creatinine and serum albumin upon ICU admission, Charlson comorbidity index, and receipt of ventilation, hemodialysis, antibiotics, CDI, C. diffi cile infection; ICU, intensive care unit; PPI, proton pump inhibitor.
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previously been associated with CDI, were not independently associated with CDI in this cohort (23) (24) (25) (40) (41) (42) (43) . In the ICU setting, compared with other settings, luminal penetration of antibiotics and other factors may fundamentally change the relationship between certain antibiotic classes and risk for CDI. Interestingly, intravenous vancomycin, a relatively narrow spectrum antibiotic aff ecting Gram-positive organisms such as C. diffi cile , was associated with CDI. Previous studies in hospitalized patients have had similar fi ndings ( 44 ) . Th e dynamics of C. diffi cile proliferation are complex, and C. diffi cile proliferation may be promoted by relatively brief courses of antibiotics such as vancomycin that are subsequently discontinued ( 45 ) . A recent study in mice demonstrated that treatment with oral vancomycin markedly disrupts the microbiome and enables colonization by nosocomial pathogens ( 46 ) . Our study was not designed to address the dynamics of antibiotic use and risk for CDI in the ICU. Antibiotics alter the colonic microbiome and reduce fecal microbial diversity. PPIs may also alter the colonic microbiome and thus may infl uence risk for CDI. Fecal microbial diversity is reduced in patients who subsequently develop CDI ( 31 ) and patients admitted to the ICU have extraordinarily low fecal microbial diversity and a high risk for CDI ( 32 ) . However, the data regarding PPIs and fecal microbial diversity is mixed. A study using 16S rRNA sequencing showed lower total sequence counts for bacteria in fecal samples from patients taken aft er initiation of PPIs but no changes in fecal microbial diversity ( 47 ) . Two larger studies found that PPIs were associated with decreased fecal microbial diversity ( 48, 49 ) and a population-based Dutch study found that PPIs explained a greater degree of interindividual variability in the fecal microbiome than any other single medication ( 50 ) . A prospective crossover trial of PPIs found no within-individual change in fecal microbial diversity aft er PPIs, but did fi nd changes in specifi c bacterial taxa that have previously been associated with CDI ( 51 ). In sum, most experimental evidence suggests that PPIs probably do change the colonic microbiome but that these changes are relatively subtle.
In this study, we found no evidence that PPIs increased risk for CDI in the ICU setting of low baseline colonic microbial diversity and we found an inverse association between PPIs and CDI among those on antibiotics. Overall, our data are consistent with experimental data showing that any eff ect of PPIs on the fecal microbiome and consequently on risk for CDI is modest compared with the eff ect of antibiotics. When patients are receiving concurrent antibiotics, the eff ect of PPIs on specifi c colonic bacteria may be overwhelmed. In fact, PPIs were associated with reduced risk for CDI in patients who were receiving antibiotics in our study. Because PPIs appear to increase predominantly Gram-positive, aerobic organisms, these same bacteria may confer a protective eff ect against CDI aft er antibiotic-induced depletion of colonic anaerobes ( 51, 52 ) . Future studies should test the hypothesis that the eff ect of PPIs on risk for CDI is mediated by the underlying colonic microbial composition.
In meta-analyses, PPIs have been associated with health-care facility-onset CDI, but there are little data focused exclusively on ICU patients, and the existing data are mixed. Several ICUbased studies found that PPIs were associated with CDI ( 53-55 ), whereas other studies did not ( 22, 40 ) . Although these studies adjusted for concurrent use of antibiotics, none of them performed a stratifi ed analysis to test whether the nature of the relationship between PPIs and CDI diff ered in patients based on whether or not they received concurrent antibiotics. One study conducted in in-patients suggested that the risk for CDI associated with PPIs was more pronounced in those who were not taking antibiotics compared with those who were taking high-risk antibiotics ( 56 ) . MacLaren et al. ( 55 ) used propensity score-adjusted models to compare patients who received PPIs to those who received H2RAs in the ICU and found a small but statistically signifi cant 29% relative increase in risk for CDI associated with PPIs. In our data, ICU patients selected to receive H2RAs had lower rates for CDI than patients who received no acid suppression. Patients selected to receive H2RAs instead of PPIs in the ICU may have uniquely low risk for CDI because these patients may fundamentally diff er from other ICU patients in ways that are diffi cult or impossible to adjust for adequately. We found no association between PPIs and risk for CDI in our study, which compared patients who received PPIs to all other patients.
Elevated serum creatinine and admission to a neurological ICU were associated with increased risk for CDI. Impaired renal function has been shown to induce alterations in tight junctions between intestinal epithelial cells, intestinal barrier function, and the gastrointestinal microbiome ( 57 ) . Renal dysfunction has also been associated with CDI in the ICU ( 25, 43 ) . Finally, our study found that ICU type may aff ect the risk for CDI. Th is may refl ect purely local conditions-only two neurological ICUs were included in this study-or the eff ect of unmeasured neurological risk factors.
Our study has multiple strengths. It is the largest study of healthcare facility-onset CDI in the ICU to date, with data from several institutions and ICUs. We used automated capture of key exposure and demographic variables including patient comorbidities, which permitted a cohort rather than a case-control study design. Finally, we conducted time-varying analyses to assess exposures that occurred within the ICU, which best refl ects current understanding of the mechanism linking PPIs and other exposures to CDI. Our study also has limitations. We were unable to assess for all potential covariates that may impact risk for CDI, including the presence or absence of non-C. diffi cile infections ( 40 ). We could not accurately ascertain the indications for particular antibiotics. Data to compute traditional scores for severity of illness in the ICU (e.g., APACHE or SAPS) were not readily accessible, and instead we used the Charlson comorbidity index to approximate the burden of comorbid diseases ( 58 ) . Our ability to capture recent CDI at other institutions was limited. However, when we reanalyzed our data including patients with known prior CDI, there was no substantive diff erence in our fi ndings.
In conclusion, in this large study of patients admitted to any one of 14 ICUs for >3 days, exposure to antibiotics was the dominating risk factor associated with health-care facility-onset CDI in the ICU. Th e relationship between PPIs and CDI was modifi ed by exposure to antibiotics, but PPIs were not associated with significantly increased risk for CDI in either those who did or in those
